Skip to main content
SHPH logo

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Stock Price & Analysis

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $3.90 (+2.01%), as of the Nov 19, 2026 trading session; market cap $18.6M.

Educational signal · not a buy or sell recommendation · How to read this

$3.90 +$0.077 (+2.01%) Market Cap $18.6M

Shuttle Pharmaceuticals Holdings, Inc. · SHPH · NASDAQ

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing drugs to improve the effectiveness of radiation therapy for cancer treatment. Their lead products, Ropidoxuridine and Doranidazole, target brain tumors, soft tissue sarcomas, and pancreatic, lung, and liver cancers, respectively.

Price as of Nov 19, 2026

Key Statistics

32 of 100

MoonshotScore v2 · Shuttle Pharmaceuticals Holdings (SHPH)

Weak
Business Quality Thin (35)
Financial Safety Strained (20)
Valuation Rich (38)
Growth Durability Flat (46)
Momentum Slipping (36)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, a fragile balance sheet and an expensive valuation, though growth is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Strained; Valuation: Rich; Growth Durability: Flat; Momentum: Slipping.

  • Altman Z -1.81 · Piotroski F 1

Holding back: balance-sheet strain

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for SHPH (57 recorded, newest six shown)
RecordedScoreBand
33Weak
32Weak
32Weak
32Weak
32Weak
32Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$3.90
Change on the day+2.01%
Market capitalisation$18.6M—
Shares traded on the day31.3K

Price & events

Other perspectives

Council score for Shuttle Pharmaceuticals Holdings (SHPH): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Weak
Valuation Weak
Growth Durability Neutral
Momentum Weak

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Jun 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Jun 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Shuttle Pharmaceuticals Holdings (SHPH), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is listed on NASDAQ. It employs 2 people. The market values it at $18.6M.

3 · Financial strengths and risks

What are the financial strengths and risks for Shuttle Pharmaceuticals Holdings (SHPH)?

Short answer · as of

What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z -1.81 · Piotroski F 1. Trailing ratios: ROA -45.0% · current ratio 0.11 · earnings yield -194.0% · free-cash-flow yield -26.4%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -1.81 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does Shuttle Pharmaceuticals Holdings compare with its peers?

Short answer

Shuttle Pharmaceuticals Holdings's score ranks tied for 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Incannex Healthcare Limited (IXHL) Same industry, near in market value$1.74 Nov 19, 2026$21.8M48 5-pillar Nov 18, 2026
TherapeuticsMD, Inc. (TXMD) Same industry, near in market value$1.81 Nov 18, 2026$21.0M34 5-pillar Nov 18, 2026
Shuttle Pharmaceuticals Holdings (SHPH) — this page$3.90$18.6M32
Zhengye Biotechnology Holding Limited (ZYBT) Same industry, near in market value$1.50 Nov 18, 2026$71.1M32 5-pillar Nov 18, 2026
Talphera, Inc. (TLPH) Same industry, near in market value$0.74 Nov 19, 2026$38.4M31 5-pillar Nov 18, 2026
Quantum BioPharma Ltd. (QNTM) Same industry, near in market value$1.42 Nov 19, 2026$9.13M30 5-pillar Nov 18, 2026
BioVie Inc. (BIVI) Named competitor$0.91 Nov 19, 2026$9.76M29 5-pillar Nov 18, 2026
Rockwell Medical, Inc. (RMTI) Same industry, near in market value$6.10 Nov 18, 2026$24.2M25 5-pillar Nov 18, 2026
Aytu BioPharma, Inc. (AYTU) Same industry, near in market value$2.66 Nov 18, 2026$28.9M25 5-pillar Nov 18, 2026
Biofrontera Inc. (BFRI) Same industry, near in market value$0.60 Nov 18, 2026$10.8M25 5-pillar Nov 18, 2026
CPHI (CPHI) Same industry, near in market value$0.50 Nov 19, 2026$21.7M23 5-pillar Nov 18, 2026
COSM (COSM) Same industry, near in market value$2.87 Nov 19, 2026$14.4M23 5-pillar Nov 18, 2026
SCYNEXIS, Inc. (SCYX) Same industry, near in market value$2.60 Nov 19, 2026$25.9M23 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 14, 2026

Transactions
11
Identified insiders
1
Purchases
6
Sales
5
Other transactions
0

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SHPH in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SHPH in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Shuttle Pharmaceuticals Holdings (SHPH)?

Read these with our analysis →

What Investors Ask About Shuttle Pharmaceuticals Holdings (SHPH)

These answers are editorial: 1 of these 9 answers is drawn from the SHPH research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for SHPH?

SHPH carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is SHPH a good stock to buy?

Stock Expert AI does not rate SHPH buy, sell or hold. Shuttle Pharmaceuticals Holdings, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the SHPH stock price today?

The last price recorded for Shuttle Pharmaceuticals Holdings, Inc. (SHPH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for SHPH?

Shuttle Pharmaceuticals faces several key risks inherent to clinical-stage pharmaceutical companies. These include the risk of clinical trial failures, which could significantly impact the company's valuation and future prospects.

What are the key factors to evaluate for SHPH?

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) holds a MoonshotScore in the low range. The timing and impact of strategic partnerships are uncertain but could provide a significant boost to the company's growth prospects. Not financial advice.

How frequently does SHPH data refresh on this page?

SHPH's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven SHPH's recent stock price performance?

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a specific niche within cancer therapy (radiation sensitization). See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider SHPH overvalued or undervalued right now?

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of SHPH?

Fractional-share availability for Shuttle Pharmaceuticals Holdings, Inc. (SHPH) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 10 figures on this page — 6 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.